“miR-484 suppresses proliferation and epithelial-mesenchymal transition by targeting ZEB1 and SMAD2 in cervical cancer cells” published in Cancer cell international was retracted as a result of concerns/issues about data and duplication of image. Here, SMAD2 is linked to cervical carcinoma.